We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Healthcare Revolution Predicted with Rise of Genomic Testing for Personalized Medicine

By LabMedica International staff writers
Posted on 04 Mar 2015
A new Frost & Sullivan (Mountain View, CA, USA) analysis has found that the direct-to-individual sector of genomic testing is now thriving, though not without criticism about the potential medical interpretation of some forms of tests that may have been initially requested for nonmedical purposes, such as those for genealogy analysis.

For personalized medicine, the need to better understand an individual’s genetic information has risen. More...
This emerging branch has given birth to companies providing tests to help understand genetic profiles and assess predisposition to inherited and other diseases. From new analysis, Frost & Sullivan reports in “Future of Genomic Testing” that with reduction in sequencing costs companies are providing affordable genetic tests directly to the individuals being tested, generally via e-commerce. However, the clinical accuracy of direct-to-consumer tests has come under scrutiny since single nucleotide polymorphism (SNP)-based sequencing is not as accurate as more expensive technology platforms such as whole exome or whole genome sequencing.

“Stringent protocols and standardization policies need to be put in place to separate medically-viable genetic tests from the ones catering to sheer curiosity,” said research analyst Madhumitha Rangesa, “The entire industry requires a gold standard approach that establishes a foundation for the development of advanced genetic tests.” Also, genetic information available to the public and stored infinitely in a virtual e-space will bring multiple safety and ethical implications. Apprehensions on potential segregation that could take place, especially by health or life insurance providers, cannot be ignored. And ownership rights of genetic information are not well-regulated, another cause for concern.

Genetic service companies must partner with or hire genetic counselors to clarify and explain test results to end-users in order to improve medical interventions, facilitate informed decisions, and raise awareness on legal issues. To ensure accuracy and credibility, small companies are collaborating with larger laboratories that have the necessary certifications and lab protocols.

“To further enhance genetic tests, several national initiatives that boost funding opportunities have been deployed,” added M. Rangesa, “Organizations like the National Institute of Health are heavily sponsoring academics and industrial research to encourage innovation in this rapidly-evolving landscape.”

The new report, part of the Technical Insights subscription, provides technology snapshots and trends in genomic testing as well as an impact assessment of key players and their pertinent business models. Following extensive interviews with market participants, Frost & Sullivan's expert analysts thoroughly examined whole exome, whole genome, SNP-based, and array-based sequencing.

Related Links:

Frost & Sullivan




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.